Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative QBECO in Patients With Colorectal Liver Metastases Undergoing Resection
NCT05677113Phase 2Active, not recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Aug 2023
- Primary completion
- Feb 2027
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing QBECO with Placebo (2 arms). Primary endpoint: Progression-Free Survival at 2 years. Started Aug 2023; status: active, not recruiting.
02
Drugs
QBECO SSI
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05677113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677113.